NEW YORK (GenomeWeb) – Proove Biosciences announced today that it has acquired Algynomics, a research-stage pain diagnostics company.

Terms of the deal were not disclosed.

Algynomics's platform and patient cohorts provide prospective data to identify individuals at increased risk for chronic pain, Proove said. Such research can be used to target pain prevention efforts, enhance patient stratification in clinical trials to identify treatment responders, produce more sensitive criteria for trial enrollment, and develop algorithms to tailor treatment for pain.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.